How do you rank among your peers when it comes to compensation packages?
Published by the editors of BioWorld Today, the new BioWorld Executive Compensation Report 2010 provides you with a variety of perspectives on compensation issues by means of key statistics and graphic analyses. This critical examination of executive compensation is a must-have for anyone directly involved in executive compensation within the biotechnology industry!
Carping Over PARPs: Buyout Equals 'Negative' for BioMarin?
With promising early data and a clear Phase III pathway for its GALNS drug in a rare lysosomal storage disorder, BioMarin Pharmaceuticals Inc. said it is no longer in critical need of late-stage assets to fill out its pipeline. (BioWorld Today)
Health Care Reform is Dead; Long Live Health Care Reform!
What did President Obama, backed by one of the largest Democratic majorities in history, accomplish in his first year in the Oval Office? A recent parody on Saturday Night Live summed it up: "When you look at my record, it's very clear what I've done so far. And that is . . . nothing. Nada." (BioWorld Perspectives)
Merus Gets $30M for 'Simple' Antibody Cocktail Platform
Merus BV, which is developing a novel antibody platform, raised €21.7 million (US$30.3 million) in a Series B round and entered a license option agreement with Novartis AG potentially worth more than $200 million in up-front and milestone payments. (BioWorld International)
